Search

Your search keyword '"Grignano, Eric"' showing total 40 results
Start Over Author "Grignano, Eric"
40 results on '"Grignano, Eric"'

2. Metformin reduces the clonal fitness of Dnmt3aR878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state

Author

Chan, Steven, primary, Hosseini, Mohsen, additional, Voisin, Veronique, additional, Chegini, Ali, additional, Varesi, Angelica, additional, Cathelin, Severine, additional, Ayyathan, Dhanoop Manikoth, additional, Liu, Alex, additional, Yang, Yitong, additional, Wang, Vivian, additional, Maher, Abdula, additional, Grignano, Eric, additional, Haines, Julie, additional, D'Alessandro, Angelo, additional, Young, Kira, additional, Wu, Yiyan, additional, Fiumara, Martina, additional, Ferrari, Samuele, additional, Naldini, Luigi, additional, Gaiti, Federico, additional, Pai, Shraddha, additional, Schimmer, Aaron, additional, Bader, Gary, additional, Dick, John, additional, Xie, Stephanie Z., additional, and Trowbridge, Jennifer, additional

Published
2024
Full Text
View/download PDF

4. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis

Author

Vazquez, Romain, Breal, Claire, Zalmai, Loria, Friedrich, Chloe, Almire, Carole, Contejean, Adrien, Barreau, Sylvain, Grignano, Eric, Willems, Lise, Deau-Fischer, Benedicte, Franchi, Patricia, Vignon, Marguerite, Decroocq, Justine, Birsen, Rudy, Goldwirt, Lauriane, Kaltenbach, Sophie, Couronne, Lucile, Fontenay, Michaela, Kosmider, Olivier, Bouscary, Didier, and Chapuis, Nicolas

Published
2021
Full Text
View/download PDF

6. Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies

Author

Breal, Claire, primary, Beuvon, Frederic, additional, de Witasse-Thezy, Thibault, additional, Dermine, Solene, additional, Franchi-Rezgui, Patricia, additional, Deau-Fisher, Benedicte, additional, Willems, Lise, additional, Grignano, Eric, additional, Contejean, Adrien, additional, Bouscary, Didier, additional, Faillie, Jean Luc, additional, Treluyer, Jean-Marc, additional, Guerin, Corinne, additional, Chouchana, Laurent, additional, and Vignon, Marguerite, additional

Published
2023
Full Text
View/download PDF

7. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review

Author

Grignano, Eric, Mekinian, Arsene, Braun, Thorsten, Liozon, Eric, Hamidou, Mohamed, Decaux, Olivier, Puéchal, Xavier, Kahn, Jean Emmanuel, Schoindre, Yoland, Rossignol, Julien, Lortholary, Olivier, Lioger, Bertrand, Hermine, Olivier, Park, Sophie, Ades, Lionel, Montestruc, François, Ricard, Laure, Gardin, Claude, Fenaux, Pierre, and Fain, Olivier

Published
2016
Full Text
View/download PDF

8. Pharmaceutical cancer care for haematology patients on oral anticancer drugs: Findings from an economic, clinical and organisational analysis

Author

Zerbit, Jeremie, primary, Kroemer, Marie, additional, Fuchs, Basile, additional, Detroit, Marion, additional, Decroocq, Justine, additional, Vignon, Marguerite, additional, Willems, Lise, additional, Deau‐Fischer, Bénédicte, additional, Franchi, Patricia, additional, Deschamps, Paul, additional, Contejean, Adrien, additional, Grignano, Eric, additional, Fouquet, Guillemette, additional, Birsen, Rudy, additional, Mondesir, Johanna, additional, Rocquet, Mathieu, additional, Huon, Jean‐François, additional, Batista, Rui, additional, Marty‐Reboul, Jeanne, additional, and Bouscary, Didier, additional

Published
2022
Full Text
View/download PDF

10. Additional file 1 of Antimicrobial stewardship in high-risk febrile neutropenia patients

Author

Contejean, Adrien, Abbara, Salam, Chentouh, Ryme, Alviset, Sophie, Grignano, Eric, Gastli, Nabil, Casetta, Anne, Willems, Lise, Canouï, Etienne, Charlier, Caroline, Pène, Frédéric, Charpentier, Julien, Reboul-Marty, Jeanne, Batista, Rui, Bouscary, Didier, and Kernéis, Solen

Subjects
hemic and lymphatic diseases
Abstract

Additional file 1: Local high-risk febrile neutropenia guidelines.

Published
2022
Full Text
View/download PDF

11. Ferroptose et cancer: Implications physiopathologiques et thérapeutiques

Author

Birsen, Rudy, Grignano, Eric, CHAPUIS, Nicolas, Bouscary, Didier, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

International audience; La ferroptose est un processus conduisant à la mort de la cellule avec, pour évènement final, l’accumulation létale de lipides peroxydés. Le fer libre intracellulaire est au centre des réactions entraînant la formation de ces lipides peroxydés. Un système antioxydant dédié à la détoxification de ces lipides permet de prévenir la mort cellulaire. Le processus de ferroptose est impliqué dans un grand nombre de maladies, notamment dans la pathogénie des maladies neurodégénératives et infectieuses et du cancer. Nous présentons dans cette revue les principaux acteurs cellulaires qui contrôlent la ferroptose et proposons une synthèse des données actuelles impliquant ce processus dans le cancer.

Published
2021

12. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study

Author

Mekinian, Arsène, Grignano, Eric, Braun, Thorsten, Decaux, Olivier, Liozon, Eric, Costedoat-Chalumeau, Nathalie, Kahn, Jean-Emmanuel, Hamidou, Mohammed, Park, Sophie, Puéchal, Xavier, Toussirot, Eric, Falgarone, Géraldine, Launay, David, Morel, Nathalie, Trouiller, Sébastien, Mathian, Alexis, Gombert, Bruno, Schoindre, Yoland, Lioger, Bertrand, De Wazieres, Benoit, Amoura, Zahir, Buchdaul, Anne-Laure, Georgin-Lavialle, Sophie, Dion, Jérémie, Madaule, Serge, Raffray, Loïc, Cathebras, Pascal, Piette, Jean Charles, Rose, Christian, Ziza, Jean Marc, Lortholary, Olivier, Montestruc, Francois, Omouri, Mohammed, Denis, Guillaume, Rossignol, Julien, Nimubona, Stanislas, Adès, Lionel, Gardin, Claude, Fenaux, Pierre, and Fain, Olivier

Published
2016
Full Text
View/download PDF

13. Ferroptose et cancer

Author

Birsen, Rudy, primary, Grignano, Eric, additional, Chapuis, Nicolas, additional, and Bouscary, Didier, additional

Published
2021
Full Text
View/download PDF

14. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study

Author

Péan de Ponfilly-Sotier, Marie, primary, Jachiet, Vincent, additional, Benhamou, Ygal, additional, Lahuna, Constance, additional, De Renzis, Benoit, additional, Kottler, Diane, additional, Voillat, Laurent, additional, Dimicoli-Salazar, Sophie, additional, Banos, Anne, additional, Chauveheid, Marie-Paule, additional, Alexandra, Jean-François, additional, Grignano, Eric, additional, Liferman, François, additional, Laborde, Mathilde, additional, Broner, Jonathan, additional, Michel, Marc, additional, Lambotte, Olivier, additional, Laribi, Kamel, additional, Venon, Marie-Dominique, additional, Dussol, Bertrand, additional, Martis, Nihal, additional, Thepot, Sylvain, additional, Park, Sophie, additional, Couret, David, additional, Roux-Sauvat, Marielle, additional, Terriou, Louis, additional, Hachulla, Eric, additional, Bally, Cécile, additional, Galland, Joris, additional, Allain, Jean-Sébastien, additional, Parcelier, Anne, additional, Peterlin, Pierre, additional, Cohen-Bittan, Judith, additional, Regent, Alexis, additional, Ackermann, Felix, additional, Le Guen, Julien, additional, Algrin, Caroline, additional, Charles, Pierre, additional, Daguindau, Etienne, additional, Puechal, Xavier, additional, Dunogue, Bertrand, additional, Blanchard-Delaunay, Claire, additional, Beyne-Rauzy, Odile, additional, Grobost, Vincent, additional, Schmidt, Jean, additional, Le Gallou, Thomas, additional, Dubos-Lascu, Georgeta, additional, Sonet, Anne, additional, Denis, Guillaume, additional, Roy-Peaud, Frédérique, additional, Fenaux, Pierre, additional, Adès, Lionel, additional, Fain, Olivier, additional, and Mekinian, Arsène, additional

Published
2021
Full Text
View/download PDF

15. From Iron Chelation to Overload as a Therapeutic Strategy to Induce Ferroptosis in Leukemic Cells

Author

Grignano, Eric, Birsen, Rudy, Chapuis, Nicolas, and Bouscary, Didier

Subjects
reactive oxygen species, ferritinophagy, iron, Oncology, Mini Review, acute myeloid leukemia, ferroptosis
Abstract

Despite its crucial importance in numerous physiological processes, iron also causes oxidative stress and damage which can promote the growth and proliferation of leukemic cells. Iron metabolism is strictly regulated and the related therapeutic approaches to date have been to restrict iron availability to tumor cells. However, since a new form of iron-catalyzed cell death has been described, termed ferroptosis, and subsequently better understood, iron excess is thought to represent an opportunity to selectively kill leukemic cells and spare normal hematopoietic cells, based on their differential iron needs. This review summarizes the physiology of iron metabolism and its deregulation in leukemia, the known ferrotoposis pathways, and therapeutic strategies to target the altered iron metabolism in leukemia for the purposes of initiating ferroptosis in these cancer cells.

Published
2020

16. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia

Author

Birsen, Rudy, primary, Larrue, Clement, additional, Decroocq, Justine, additional, Johnson, Natacha, additional, Guiraud, Nathan, additional, Gotanegre, Mathilde, additional, Cantero-Aguilar, Lilia, additional, Grignano, Eric, additional, Huynh, Tony, additional, Fontenay, Michaela, additional, Kosmider, Olivier, additional, Mayeux, Patrick, additional, Chapuis, Nicolas, additional, Sarry, Jean Emmanuel, additional, Tamburini, Jerome, additional, and Bouscary, Didier, additional

Published
2021
Full Text
View/download PDF

19. Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML

Author

Hormi, Myriam, primary, Birsen, Rudy, additional, Belhadj, Maya, additional, Huynh, Tony, additional, Cantero Aguilar, Lilia, additional, Grignano, Eric, additional, Haddaoui, Lamya, additional, Guillonneau, Francois, additional, Mayeux, Patrick, additional, Hunault, Mathilde, additional, Tamburini, Jérôme, additional, Kosmider, Olivier, additional, Fontenay, Michaela, additional, Bouscary, Didier, additional, and Chapuis, Nicolas, additional

Published
2020
Full Text
View/download PDF

22. High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah’s Witnesses patients: a feasible option in the age of hematopoietic growth factors

Author

Perol, Louis, primary, Grignano, Eric, additional, Contejean, Adrien, additional, Gastaud, Lauris, additional, Legoff, Marielle, additional, Franchi, Patricia, additional, Deau-Fischer, Bénédicte, additional, Willems, Lise, additional, Bouscary, Didier, additional, and Tamburini, Jerome, additional

Published
2019
Full Text
View/download PDF

23. Acute and fatal cephalosporin‐induced autoimmune haemolytic anaemia.

Author

Boilève, Alice, Gavaud, Ariane, Grignano, Eric, Franck, Nathalie, Carlotti, Agnès, Mira, Jean‐Paul, Bouscary, Didier, and Jozwiak, Mathieu

Subjects
AUTOIMMUNE hemolytic anemia, CEFTRIAXONE, HEMOLYTIC anemia, MULTIPLE organ failure, MEDICAL care, CEPHALOSPORINS, INTENSIVE care units
Abstract

We report the case of an 82‐year old male patient admitted in our medical intensive care unit for diffuse skin lesions, 3 days after the onset of ceftriaxone for bilateral pneumonia without microbiological documentation. The patient concomitantly exhibited diffuse skin lesions compatible with livedo and neurological and haemodynamic failure. Biological analysis revealed acute haemolytic anaemia. Warming of patient, red blood‐cells transfusion and high‐doses corticosteroids were initiated and ceftriaxone was stopped. Despite these therapeutics, the patient exhibited multiple organ failure and died. The main suspected triggering factor of this acute and fatal haemolytic anaemia was ceftriaxone administration considering: (i) the delay between cephalosporin administration and symptoms; (ii) the worsening of livedo and acrocyanosis a few hours after meningeal ceftriaxone doses; and (iii) fatal evolution. Cephalosporin‐induced autoimmune haemolytic anaemia is a rare and serious cause of livedo that should be suspected in patients exhibiting livedo and acute haemolytic anaemia within hours/days following cephalosporin administration. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

24. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia

Author

Fraison, Jean-Baptiste, Mekinian, Arsène, Grignano, Eric, Kahn, Jean-Emmanuel, Arlet, Jean-Benoit, Decaux, Olivier, Denis, Guillaume, Buchdahl, Anne-Laure, Omouri, Mohamed, Maigne, Gwenola, Aouba, Achille, Leon, Nathalie, Berthier, Sabine, Liozon, Eric, Park, Sophie, Gardin, Claude, Lortholary, Olivier, Rossignol, Julien, Fenaux, Pierre, Fain, Olivier, and Braun, Thorsten

Published
2016
Full Text
View/download PDF

26. Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients

Author

Mekinian, Arsene, primary, Dervin, Guillaume, additional, Lapidus, Nathanael, additional, Kahn, Jean-Emmanuel, additional, Terriou, Louis, additional, Liozon, Eric, additional, Grignano, Eric, additional, Piette, Jean-Charles, additional, Rauzy, Odile Beyne, additional, Grobost, Vincent, additional, Godmer, Pascal, additional, Gillard, Jerome, additional, Rossignol, Julien, additional, Launay, David, additional, Aouba, Achille, additional, Cardon, Thierry, additional, Bouillet, Laurence, additional, Broner, Jonathan, additional, Vinit, Julien, additional, Ades, Lionel, additional, Carrat, Fabrice, additional, Salvado, Clementine, additional, Toussirot, Eric, additional, Versini, Mathilde, additional, Costedoat-Chalumeau, Nathalie, additional, Fraison, Jean Baptiste, additional, Guilpain, Philippe, additional, Fenaux, Pierre, additional, and Fain, Olivier, additional

Published
2017
Full Text
View/download PDF

28. Inflammatory arthritis in patients with myelodysplastic syndromes: a multicenter retrospective study and literature review of 68 cases

Author

Mekinian, Arsène, Braun, Thorsten, Decaux, Olivier, Falgarone, Géraldine, Toussirot, Eric, Raffray, Loïc, Omouri, Mohamed, Gombert, Bruno, De Wazieres, Benoit, Buchdaul, Anne-Laure, Ziza, Jean-Marc, Launay, David, Denis, Guillaume, Madaule, Serge, Rose, Christian, Grignano, Eric, Fenaux, Pierre, Fain, Olivier, Inflammation (CRI), Groupe Francophone Des Myélodysplasies (GFM), (SNFMI), Société Nationale Française, Service de Médecine Interne [Rennes], CHU Pontchaillou [Rennes], Department of Rheumatology, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Physiopathologie, cibles et thérapies de la polyarthrite rhumatoïde (Li2P), Université Paris 13 (UP13)-Université Sorbonne Paris Cité (USPC)-UFR Santé, Médecine et Biologie Humaine-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Rhumatologie, Hôpital Jean Minjoz, Université Bordeaux Segalen - Bordeaux 2, Service de médecine gériatrique, Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Department of Internal Medicine, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Claude Huriez, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'hématologie clinique [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris 13 (UP13)-Hôpital Avicenne, service de médecine interne, Université Paris 13 (UP13)-Hôpital Jean Verdier [Bondy], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Hôpital Claude Huriez [Lille], CHU Lille, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Université Paris 13 (UP13)-Hôpital Jean Verdier [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Male, medicine.medical_specialty, Inflammatory arthritis, Arthritis, Gastroenterology, Etanercept, Interquartile range, Sulfasalazine, Internal medicine, medicine, 80 and over, Humans, Original Study, Glucocorticoids, Aged, Retrospective Studies, Aged, 80 and over, [SDV.GEN]Life Sciences [q-bio]/Genetics, business.industry, Myelodysplastic syndromes, Hydroxychloroquine, General Medicine, medicine.disease, 3. Good health, Surgery, Treatment Outcome, Polymyalgia Rheumatica, Myelodysplastic Syndromes, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Polyarthritis, Female, France, business, medicine.drug
Abstract

Supplemental Digital Content is available in the text., We describe the characteristics and outcome of inflammatory arthritis in patients with myelodysplastic syndrome (MDS) in a French multicenter retrospective study. Twenty-two patients with MDS (median age, 77.5 yr [interquartile range, 69–81]; 10 women) were included. Inflammatory arthritis presented as polyarthritis in 17 cases (77%) and with symmetric involvement in 15 cases (68%). At diagnosis, the median disease activity score 28 based on C-reactive protein (DAS28-CRP) was 4.5 [2–6.5]. Two patients had anti-citrullinated protein antibodies (ACPAs), and 1 had radiologic erosions. The median time between the diagnoses of arthritis and MDS was 10 months [6–42], with a median articular symptom duration of 3 months [2–8]. The diagnosis of both diseases was concomitant in 6 cases (27%); arthritis preceded MDS in 12 cases (55%), and occurred after MDS in 4 (18%). While the number of swollen and tender joints significantly decreased during follow-up, as did the median DAS28-CRP (from 4.3 [3.8–4.6] at baseline to 2.9 [1.75–3.3]; p < 0.05), CRP remained elevated (CRP >20 mg/L) in 8 patients (42%). Nevertheless, radiographic progression and new ACPA positivity were not observed during a median follow-up of 29 months [9–76]. While most of the patients were treated with steroids (n = 16) for arthritis, additional treatment was administered in only 4 patients (hydroxychloroquine, n = 2; sulfasalazine [Salazopyrin] and etanercept, n = 1, respectively). Eleven patients died during follow-up from acute myeloid leukemia (n = 5); infections (n = 3); or cerebral bleeding, cardiorespiratory failure, or undetermined cause (n = 1, respectively). Inflammatory arthritis associated with MDS can have various presentations and is often seronegative and nonerosive. Steroids alone are the most common treatment in MDS-associated arthritis, but that treatment is insufficient to control arthritis. Steroid-sparing strategies need to be identified.

Published
2014

30. Efficacy of Azacitidine (AZA) in Autoimmune and Inflammatory Disorders (AID) Associated with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Author

Fraison, Jean-Baptiste, primary, Mekinian, Arsène, additional, Grignano, Eric, additional, Kahn, Jean-Emmanuel, additional, Arlet, Jean-Benoît, additional, Decaux, Olivier, additional, Guillaume, Denis, additional, Buchdahl, Anne-Laure, additional, Omouri, Mohamed, additional, Maigne, Gwenola, additional, Aouba, Achille, additional, Leon, Nathalie, additional, Berthier, Sabine, additional, Liozon, Eric, additional, Park, Sophie, additional, Gardin, Claude, additional, Lortholary, Olivier, additional, Rossignol, Julien, additional, Fenaux, Pierre, additional, Fain, Olivier, additional, and Braun, Thorsten, additional

Published
2015
Full Text
View/download PDF

31. Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.

Author

Jachiet, Vincent, Mekinian, Arsène, Carrat, Fabrice, Grignano, Eric, Retbi, Aurelia, Boffa, Jean-Jacques, Ronco, Pierre, Rondeau, Eric, Sellam, Jérémie, Berenbaum, Francis, Chazouillères, Olivier, Capron, Jean, Alamowitch, Sonia, Chasset, Francois, Frances, Camille, Coppo, Paul, Fain, Olivier, and on behalf of French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON)

Subjects
LYMPHOMAS, AUTOIMMUNITY, HODGKIN'S disease, B cell lymphoma, CHRONIC lymphocytic leukemia, PATIENTS
Abstract

This French multicenter retrospective cohort study aimed to describe the autoimmune manifestations (AIMs) associated with lymphoma among patients hospitalized between 2005 and 2016 in three French University Hospitals. Among 2503 patients with lymphoma, 108 (4.3%) had AIMs, mostly autoimmune cytopenias (71.3%), neurological diseases (10.2%), kidney diseases (6.5%), systemic vasculitis (5.6%) and others. As compared with the 2395 lymphoma patients without AIMs, those with AIMs were older (p = .01), more frequently had B-cell chronic lymphocytic leukemia (p < .01) and less frequently diffuse large B-cell lymphomas (p = .01) and Hodgkin lymphoma (p = .01). The 5-year overall survival with lymphoma was 65% and 79% (p = .03) with and without AIMs. This large cohort study shows that various types of AIMs, mostly cytopenias, could be associated with lymphoma and affect the overall outcome with lymphoma, in particular for B-cell non-Hodgkin lymphoma (p = .01) and T-cell non-Hodgkin lymphoma (p = .01), with no survival difference noted for other types of lymphoma (p = .2). [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

32. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study

Author

Mekinian, Arsène, primary, Grignano, Eric, additional, Braun, Thorsten, additional, Decaux, Olivier, additional, Liozon, Eric, additional, Costedoat-Chalumeau, Nathalie, additional, Kahn, Jean-Emmanuel, additional, Hamidou, Mohammed, additional, Park, Sophie, additional, Puéchal, Xavier, additional, Toussirot, Eric, additional, Falgarone, Géraldine, additional, Launay, David, additional, Morel, Nathalie, additional, Trouiller, Sébastien, additional, Mathian, Alexis, additional, Gombert, Bruno, additional, Schoindre, Yoland, additional, Lioger, Bertrand, additional, De Wazieres, Benoit, additional, Amoura, Zahir, additional, Buchdaul, Anne-Laure, additional, Georgin-Lavialle, Sophie, additional, Dion, Jérémie, additional, Madaule, Serge, additional, Raffray, Loïc, additional, Cathebras, Pascal, additional, Piette, Jean Charles, additional, Rose, Christian, additional, Ziza, Jean Marc, additional, Lortholary, Olivier, additional, Montestruc, Francois, additional, Omouri, Mohammed, additional, Denis, Guillaume, additional, Rossignol, Julien, additional, Nimubona, Stanislas, additional, Adès, Lionel, additional, Gardin, Claude, additional, Fenaux, Pierre, additional, and Fain, Olivier, additional

Published
2015
Full Text
View/download PDF

35. Systemic Inflammatory and Autoimmune Diseases (SAID) Associated with MDS: A French Multicenter Retrospective Study

Author

Mekinian, Arsene, primary, Grignano, Eric, additional, Braun, Thorsten, additional, Olivier, Decaux, additional, Eric, Liozon, additional, Nathalie, Costedoat, additional, jean Emmanuel, Kahn, additional, Hamidou, Mohamed, additional, Puechal, Xavier, additional, Park, Sophie, additional, Toussirot, Eric, additional, Falgarone, Geraldine, additional, Launay, David, additional, Nathalie, Morel, additional, Trouiller, Sebastien, additional, Alexis, Mathian, additional, Bruno, Gombert, additional, Schoindre, Yoland, additional, Lioger, Bertrand, additional, de Wazieres, Benoit, additional, Amoura, Zahir, additional, anne Laure, Buchdaul, additional, georgin Lavialle, Sophie, additional, Jeremie, Dion, additional, Madaule, Serge, additional, Raffray, Loic, additional, Cathebras, Pascale, additional, Piette, Jean Charles, additional, Ziza, Jean Marc, additional, Rose, Christian, additional, Montestruc, Francois, additional, Lortholary, Olivier, additional, Omouri, Mohamed, additional, Denis, Guilllaume, additional, Rossignol, Julien, additional, Ades, Lionel, additional, Gardin, Claude, additional, Fenaux, Pierre, additional, and Fain, Olivier, additional

Published
2014
Full Text
View/download PDF

37. Metformin reduces the clonal fitness of Dnmt3a R878H hematopoietic stem and progenitor cells by reversing their aberrant metabolic and epigenetic state.

Author

Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Ayyathan DM, Liu ACH, Yang Y, Wang V, Maher A, Grignano E, Reisz JA, D'Alessandro A, Young K, Wu Y, Fiumara M, Ferrari S, Naldini L, Gaiti F, Pai S, Schimmer AD, Bader GD, Dick JE, Xie SZ, Trowbridge JJ, and Chan SM

Abstract

Clonal hematopoiesis (CH) arises when a hematopoietic stem cell (HSC) acquires a mutation that confers a competitive advantage over wild-type (WT) HSCs, resulting in its clonal expansion. Individuals with CH are at an increased risk of developing hematologic neoplasms and a range of age-related inflammatory illnesses 1-3 . Therapeutic interventions that suppress the expansion of mutant HSCs have the potential to prevent these CH-related illnesses; however, such interventions have not yet been identified. The most common CH driver mutations are in the DNA methyltransferase 3 alpha ( DNMT3A ) gene with arginine 882 (R882) being a mutation hotspot. Here we show that murine hematopoietic stem and progenitor cells (HSPCs) carrying the Dnmt3a R878H/+ mutation, which is equivalent to human DNMT3A R882H/+ , have increased mitochondrial respiration compared with WT cells and are dependent on this metabolic reprogramming for their competitive advantage. Importantly, treatment with metformin, an oral anti-diabetic drug with inhibitory activity against complex I in the electron transport chain (ETC), reduced the fitness of Dnmt3a R878H/+ HSCs. Through a multi-omics approach, we discovered that metformin acts by enhancing the methylation potential in Dnmt3a R878H/+ HSPCs and reversing their aberrant DNA CpG methylation and histone H3K27 trimethylation (H3K27me3) profiles. Metformin also reduced the fitness of human DNMT3A R882H HSPCs generated by prime editing. Our findings provide preclinical rationale for investigating metformin as a preventive intervention against illnesses associated with DNMT3A R882 mutation-driven CH in humans., Competing Interests: Conflicts of Interest S.M.C. has received research funding from the Centre for Oncology and Immunology in Hong Kong, Celgene/BMS, AbbVie Pharmaceuticals, Agios Pharmaceuticals, and Servier Laboratories. F.G. serves as a consultant for S2 Genomics Inc. A.D.S. has received research funding from Takeda Pharmaceuticals, BMS and Medivir AB, and consulting fees/honorarium from Takeda, Novartis, Jazz, and Otsuka Pharmaceuticals. A.D.S. is named on a patent application for the use of DNT cells to treat AML. A.D.S. is a member of the Medical and Scientific Advisory Board of the Leukemia and Lymphoma Society of Canada. A.D.S. holds the Ronald N. Buick Chair in Oncology Research. J.E.D. has received research funding from Celgene/BMS, and has patents licensed to Trillium Therapeutics/Pfizer.

Published
2024
Full Text
View/download PDF

38. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.

Author

Péan de Ponfilly-Sotier M, Jachiet V, Benhamou Y, Lahuna C, De Renzis B, Kottler D, Voillat L, Dimicoli-Salazar S, Banos A, Chauveheid MP, Alexandra JF, Grignano E, Liferman F, Laborde M, Broner J, Michel M, Lambotte O, Laribi K, Venon MD, Dussol B, Martis N, Thepot S, Park S, Couret D, Roux-Sauvat M, Terriou L, Hachulla E, Bally C, Galland J, Allain JS, Parcelier A, Peterlin P, Cohen-Bittan J, Regent A, Ackermann F, Le Guen J, Algrin C, Charles P, Daguindau E, Puechal X, Dunogue B, Blanchard-Delaunay C, Beyne-Rauzy O, Grobost V, Schmidt J, Le Gallou T, Dubos-Lascu G, Sonet A, Denis G, Roy-Peaud F, Fenaux P, Adès L, Fain O, and Mekinian A

Subjects
Case-Control Studies, Humans, Retrospective Studies, Autoimmune Diseases complications, Autoimmune Diseases epidemiology, Leukemia, Myelomonocytic, Chronic complications, Leukemia, Myelomonocytic, Chronic epidemiology, Myelodysplastic Syndromes complications, Myelodysplastic Syndromes epidemiology, Venous Thromboembolism diagnosis, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology
Abstract

Objectives: Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML) are associated with systemic inflammatory and autoimmune diseases (SIADs) in 10-30% of cases. The aims of this study were (i) to evaluate the prevalence of venous thromboembolism VTE in patients presenting with both MDS/CMML and SIADs, (ii) to describe risk factors associated with thrombosis, and (iii) to analyse the impact of VTE on overall survival and transformation to acute myeloid leukaemia in comparison to patients with MDS/CMML-associated SIADs without VTE., Methods: This retrospective multicentre case-control study was conducted among patients with MDS/CMML and dysimmune disorders and featured in the French retrospective database of the French Network of Dysimmune Disorders Associated with Hemopathies (MINHEMON), diagnosed with MDS/CMML and dysimmune disorders., Results: During a median follow-up of 16 months (5-48) VTE occurred in 35 patients (21.6 %) whereas 127 patients did not. Among those with VTE, 8 patients (22.9%) experienced two or more VTE. Common prothrombotic risk factors were not significantly different in patients with or without VTE. CMML was more frequent in patients without VTE (37 % vs. 14.3%, p=0.01), whereas myelodysplasic/myeloproliferative neoplasm (MDS/MPN) was higher in VTE patients (20 % vs. 5.5 %, p=0.01). In a multivariate analysis, only MDS/CMML progression at the time of VTE (odds ratio 28.82, 95 % CI (5.52-530.70) was significantly associated with VTE. When treated with an anticoagulation therapy, bleeding occurred in 19.4% of cases (6/31). Overall survival was not significantly different between patients with and without VTE (p=0.68). Leukaemia-free survival between groups was not significantly different (p=0.83)., Conclusions: VTE is a common complication in MDS/CMML-associated SIADSs with an increased risk of bleeding when treated by anticoagulants. In the MDS/CMML subgroup, SIADS flares and MDS/CMML progression seem to be prothrombotic risk factors.

Published
2022
Full Text
View/download PDF

39. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia.

Author

Birsen R, Larrue C, Decroocq J, Johnson N, Guiraud N, Gotanegre M, Cantero-Aguilar L, Grignano E, Huynh T, Fontenay M, Kosmider O, Mayeux P, Chapuis N, Sarry JE, Tamburini J, and Bouscary D

Subjects
Cell Death, Humans, Quinuclidines therapeutic use, Ferroptosis, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute metabolism
Abstract

APR-246 is a promising new therapeutic agent that targets p53 mutated proteins in myelodysplastic syndromes and in acute myeloid leukemia (AML). APR-246 reactivates the transcriptional activity of p53 mutants by facilitating their binding to DNA target sites. Recent studies in solid cancers have found that APR-246 can also induce p53-independent cell death. In this study, we demonstrate that AML cell death occurring early after APR-246 exposure is suppressed by iron chelators, lipophilic antioxidants and inhibitors of lipid peroxidation, and correlates with the accumulation of markers of lipid peroxidation, thus fulfilling the definition of ferroptosis, a recently described cell death process. The capacity of AML cells to detoxify lipid peroxides by increasing their cystine uptake to maintain major antioxidant molecule glutathione biosynthesis after exposure to APR-246 may be a key determinant of sensitivity to this compound. The association of APR-246 with induction of ferroptosis (either by pharmacological compounds, or genetic inactivation of SLC7A11 or GPX4) had a synergistic effect on the promotion of cell death, both in vivo and ex vivo.

Published
2022
Full Text
View/download PDF

40. [Ferroptosis and cancer: Physiopathological and therapeutic implications].

Author

Birsen R, Grignano E, Chapuis N, and Bouscary D

Subjects
Humans, Lipid Peroxidation, Lipids, Reactive Oxygen Species, Ferroptosis, Neoplasms therapy
Abstract

Ferroptosis is a process leading to cell death. The final event is the lethal accumulation of peroxidized lipids. Iron is at the center of the reactions leading to the formation of peroxidized lipids, while an antioxidant system is dedicated to the detoxification of these lipids to prevent cell death. Ferroptosis is involved in many human diseases, including the pathophysiology of neurodegenerative diseases, infection, and cancer. We will present the different cellular actors that control ferroptosis and propose a review of current data involving this cellular process in cancer., (© 2021 médecine/sciences – Inserm.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results